In fact, the efficacy of immune checkpoint inhibitors in the neoadjuvant setting remains unaffected by PDL-1 expression, which is the most common marker used to define the activity of these agents in different tumor models [2,3]. This evidence concerns the gene CD274 and neoplasm.